Literature DB >> 17191133

Relation of plasma homocysteine to plasma amyloid beta levels.

José A Luchsinger1, Ming-Xin Tang, Joshua Miller, Ralph Green, Pankash D Mehta, Richard Mayeux.   

Abstract

BACKGROUND: Elevated plasma homocysteine and amyloid beta (Abeta) have been associated with Alzheimer's disease (AD). We investigated the cross-sectional association between these biomarkers.
METHODS: We used linear regression to relate plasma homocysteine and Abeta adjusting for age, gender, creatinine, APOE-epsilon4, and ethnic group in 327 persons aged 78 +/- 6.6 years.
RESULTS: Plasma homocysteine correlated with age, serum creatinine, plasma Abeta40 and Abeta42, and was inversely correlated with serum vitamin B12, and folate. Abeta42, but not Abeta40, was related to later development of dementia. Homocysteine was related to higher Abeta40 levels (coefficient = 2.0; P < 0.0001) and this association was attenuated after adjustment for creatinine (coefficient = 1.0; P < 0.0001). The crude association between homocysteine and Abeta42 was weaker (coefficient = 0.5; P = 0.01) and became non-significant after adjustment for creatinine (coefficient = 0.4; P = 0.06). These associations were unrelated to ethnicity, the presence of APOE-epsilon4 or dementia. Analyses by quartiles of homocysteine showed that these association were driven primarily by the fourth quartile.
CONCLUSIONS: Plasma homocysteine is directly related to Abeta40. The association with Abeta42 is not significant. These results seem to indicate that homocysteine is related to aging but not specifically to AD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17191133     DOI: 10.1007/s11064-006-9207-7

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  43 in total

1.  The origins of Alzheimer disease: a is for amyloid.

Authors:  D J Selkoe
Journal:  JAMA       Date:  2000 Mar 22-29       Impact factor: 56.272

2.  Homocysteine and cognitive decline in healthy elderly.

Authors:  A McCaddon; P Hudson; G Davies; A Hughes; J H Williams; C Wilkinson
Journal:  Dement Geriatr Cogn Disord       Date:  2001 Sep-Oct       Impact factor: 2.959

Review 3.  Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease.

Authors:  Richard A Frank; Douglas Galasko; Harald Hampel; John Hardy; Mony J de Leon; Pankaj D Mehta; Joseph Rogers; Eric Siemers; John Q Trojanowski
Journal:  Neurobiol Aging       Date:  2003 Jul-Aug       Impact factor: 4.673

Review 4.  Cardiovascular risk factors and Alzheimer's disease.

Authors:  José A Luchsinger; Richard Mayeux
Journal:  Curr Atheroscler Rep       Date:  2004-07       Impact factor: 5.113

5.  Silent brain infarcts and the risk of dementia and cognitive decline.

Authors:  Sarah E Vermeer; Niels D Prins; Tom den Heijer; Albert Hofman; Peter J Koudstaal; Monique M B Breteler
Journal:  N Engl J Med       Date:  2003-03-27       Impact factor: 91.245

6.  Homocysteine as a risk factor for cognitive impairment in stroke patients.

Authors:  Perminder S Sachdev; Michael J Valenzuela; Henry Brodaty; Xing Li Wang; Jeffrey Looi; Lisa Lorentz; Lesley Howard; Megan Jones; Alessandro S Zagami; David Gillies; David E L Wilcken
Journal:  Dement Geriatr Cogn Disord       Date:  2003       Impact factor: 2.959

7.  Toxicity of substrate-bound amyloid peptides on vascular smooth muscle cells is enhanced by homocysteine.

Authors:  Su San Mok; Bradley J Turner; Konrad Beyreuther; Colin L Masters; Colin J Barrow; David H Small
Journal:  Eur J Biochem       Date:  2002-06

8.  Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland.

Authors:  Stephen P McIlroy; Kevin B Dynan; John T Lawson; Christopher C Patterson; A Peter Passmore
Journal:  Stroke       Date:  2002-10       Impact factor: 7.914

9.  Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial.

Authors:  James F Toole; M René Malinow; Lloyd E Chambless; J David Spence; L Creed Pettigrew; Virginia J Howard; Elizabeth G Sides; Chin-Hua Wang; Meir Stampfer
Journal:  JAMA       Date:  2004-02-04       Impact factor: 56.272

10.  Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid beta peptide levels.

Authors:  Javier Pacheco-Quinto; Elena B Rodriguez de Turco; Steven DeRosa; Altovise Howard; Felix Cruz-Sanchez; Kumar Sambamurti; Lorenzo Refolo; Suzana Petanceska; Miguel A Pappolla
Journal:  Neurobiol Dis       Date:  2006-03-03       Impact factor: 5.996

View more
  17 in total

1.  Plasma homocysteine and risk of mild cognitive impairment.

Authors:  Christiane Reitz; Ming-Xin Tang; Joshua Miller; Ralph Green; José A Luchsinger
Journal:  Dement Geriatr Cogn Disord       Date:  2008-12-16       Impact factor: 2.959

2.  Meta-analysis of plasma amyloid-β levels in Alzheimer's disease.

Authors:  Fei Song; Anne Poljak; Michael Valenzuela; Richard Mayeux; George A Smythe; Perminder S Sachdev
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

3.  Cross-Sectional Associations of Total Plasma Homocysteine with Cortical β-Amyloid Independently and as a Function of Omega 3 Polyunsaturated Fatty Acid Status in Older Adults at Risk of Dementia.

Authors:  C Hooper; P De Souto Barreto; N Coley; E Caussé; P Payoux; A S Salabert; M Cesari; S Andrieu; G-L Bowman; M Weiner; B Vellas
Journal:  J Nutr Health Aging       Date:  2017       Impact factor: 4.075

4.  Metformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial.

Authors:  José A Luchsinger; Thania Perez; Helena Chang; Pankaj Mehta; Jason Steffener; Gnanavalli Pradabhan; Masanori Ichise; Jennifer Manly; Davangere P Devanand; Emilia Bagiella
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

5.  Plasma amyloid beta, neurofilament light chain, and total tau in the Systolic Blood Pressure Intervention Trial (SPRINT).

Authors:  Nicholas M Pajewski; Fanny M Elahi; Manjula Kurella Tamura; Jason D Hinman; Ilya M Nasrallah; Joachim H Ix; Lindsay M Miller; Lenore J Launer; Clinton B Wright; Mark A Supiano; Alan J Lerner; Tiffany L Sudduth; Anthony A Killeen; Alfred K Cheung; David M Reboussin; Donna M Wilcock; Jeff D Williamson
Journal:  Alzheimers Dement       Date:  2021-11-17       Impact factor: 16.655

6.  Acceleration of brain amyloidosis in an Alzheimer's disease mouse model by a folate, vitamin B6 and B12-deficient diet.

Authors:  Jia-Min Zhuo; Domenico Praticò
Journal:  Exp Gerontol       Date:  2009-12-11       Impact factor: 4.032

7.  High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial.

Authors:  Paul S Aisen; Lon S Schneider; Mary Sano; Ramon Diaz-Arrastia; Christopher H van Dyck; Myron F Weiner; Teodoro Bottiglieri; Shelia Jin; Karen T Stokes; Ronald G Thomas; Leon J Thal
Journal:  JAMA       Date:  2008-10-15       Impact factor: 56.272

8.  Plasma homocysteine, Alzheimer and cerebrovascular pathology: a population-based autopsy study.

Authors:  Babak Hooshmand; Tuomo Polvikoski; Miia Kivipelto; Maarit Tanskanen; Liisa Myllykangas; Timo Erkinjuntti; Mira Mäkelä; Minna Oinas; Anders Paetau; Philip Scheltens; Elizabeth C W van Straaten; Raimo Sulkava; Alina Solomon
Journal:  Brain       Date:  2013-09       Impact factor: 13.501

9.  Plasma Amyloid-β Peptides and Homocysteine in Depression in the Homebound Elderly.

Authors:  Wei Qiao Qiu; Xiaoyan Sun; D Mkaya Mwamburi; Jacqueline Haker; David Lisle; Abishek Rizal; Yu-Min Lin; Liyan Qiao; Paul Summergrad; Marshal Folstein; Irwin Rosenberg
Journal:  N Am J Med Sci (Boston)       Date:  2010-04

10.  Homocysteine exacerbates β-amyloid pathology, tau pathology, and cognitive deficit in a mouse model of Alzheimer disease with plaques and tangles.

Authors:  Jian-Guo Li; Jin Chu; Carlos Barrero; Salim Merali; Domenico Praticò
Journal:  Ann Neurol       Date:  2014-05-28       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.